British Society for Haematology 2021: Results of a study examining nivolumab combined with brentuximab vedotin for treatment of relapsed mediastinal gray zone lymphoma.
Home / Resource Library / Nivolumab Plus Brentuximab Vedotin Shows Efficacy for Patients With Mediastinal Gray Zone Lymphoma